Vivos Inc. Demonstrates Precision in Precision Radionuclide Therapy

Stock Information for Inhibitor Therapeutics Inc

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Inhibitor Therapeutics Inc

Vivos Inc. Issues Shareholder Update Letter
Vivos Inc. Strengthens Strategic Collaboration with Exubrion Therapeutics
Vivos Inc. Retains Top FDA Regulatory Expert Dr. John J. Smith, M.D., J.D., to Support IDE Submission for RadioGel®
Vivos Inc Board Authorizes Vivos Inc to Establish a Corporate Entity in India
Vivos Inc Board Authorizes Vivios Inc to Establish a Corporate Entity in India
Vivos Inc Files Critical Patent For Hydrogel Electron Beam Sterilization
Investigational Device Exemption (IDE) Application for Human Clinical Trials at Mayo Declined By FDA
Vivos Inc. Submitted the Investigational Device Exemption (IDE) Application for Human Clinical Trials at Mayo Clinic

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.